Metabolism and Nutrition Disorder Clinical Trial
Official title:
Twenty Four Hours Amino Acid Metabolism in Fed Surgical Critically Ill Patients: a Stable Isotope Tracer Study.
Introduction Sarcopenia is defined as progressive generalized loss of skeletal muscle mass,
strength and function. Sarcopenia due to lack of physical activity is a known phenomenon and
is usually observed as a normal part of aging or in certain diseases and pathogenic
processes. Major associated factors causing development of sarcopenia may be summarized as
interactions of environmental and hormonal factors, underlying diseases, activation of
inflammatory pathways, mitochondrial dysfunction, reduced satellite cell numbers, and loss of
neuromuscular junctions.
Intensive care acquired weakness (ICU-AW) known formerly as critical illness polyneuropathy,
is a diagnosis that becomes more common as survival rates from long ICU hospitalization are
more prevalent. It is characterized by a primary axonal degeneration, without demyelination,
that typically affects motor nerves more than sensory nerves.
ICU-AW affects the limbs (particularly the lower extremities) in a symmetric pattern.
Weakness is most notable in proximal neuromuscular areas (e.g., the shoulders and hip
girdle). In addition, involvement of the respiratory muscles can occur and can impede weaning
from mechanical ventilation.
The pathophysiological mechanisms of ICU-acquired weakness are believed to be multifactorial.
Some suspected factors include dysfunctional microcirculation and hyperglycemia. It has been
shown that tight glucose control in ICU patients reduces the risk for ICU-AW (although it has
been associated with other adverse events). Sodium channels channelopathy is also a
researched cause for ICU-AW. Muscle loss in the ICU are usually related to bedridden
condition and lack of mobility, increase in ubiquitination and inadequate protein
administration associated with large negative nitrogen balance. In addition mechanical
ventilation contributes greatly to this problem. This has been particularly relevant in post
trauma/surgical long stayer patients.
In the past years great progress was made in the investigation of protein balance, breakdown
and synthesis using stable isotope tracers in various medical conditions. In a research
performed in PICU (1-5) and ICU (6, 7) regarding the measurement of plasma amino acid during
critical illness, stable phenylalanine, tyrosine leucine, arginine and citrulline isotope
were used intravenously without any safety issue problem. Another study was performed on
adults suffering from COPD with matched healthy adults, using stable isotopes of
phenylalanine, tyrosine leucine, isoleucine and valine (8). During the study the isotopes
were given parenterally as well as enterally. The study showed significant change in
splanchnic extraction of various amino acids and higher turnover of BCAA in COPD patients.
Using the theory that supplemental milk can compensate for the elevated turnover of BCAA in
COPD patients, using the isotope analysis demonstrated that this theory was proven wrong and
the conclusion was that alterations are present in BCAA metabolism despite normal plasma
levels in normal weight COPD. Further research is needed to find a way to compensate for it.
These studies and other recent studies (9-19) show us the safety regarding the use of stable
isotope tracers whether IV or PO, while giving us the opportunity to assess the metabolism of
amino acid in all sorts of pathological states.
Hypothesis & Aim of the study We think that based on current literature, there are important
differences between critically ill patients and healthy population in the amino acid profile
and distribution in the body as well as synthesis and breakdown.
The aim of the study is to measure these differences in long ICU stayers (above 7 days)
admitted in the ICU after surgical/trauma injury, and to try and help aiming future treatment
and research in this field.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05864833 -
METabolism After Orthopedic Surgery
|
||
Completed |
NCT02235961 -
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT02918279 -
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
|
Phase 3 | |
Completed |
NCT00978393 -
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
|
Phase 1 | |
Completed |
NCT03661879 -
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
|
Phase 1 | |
Completed |
NCT05024032 -
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
|
Phase 3 | |
Completed |
NCT02568306 -
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects
|
Phase 1 | |
Completed |
NCT00781937 -
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
|
Phase 3 | |
Completed |
NCT03223493 -
Awareness, Care & Treatment in Obesity Management (ACTION) Study
|
||
Completed |
NCT03308721 -
Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity
|
Phase 1 | |
Completed |
NCT02941042 -
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.
|
Phase 1 | |
Completed |
NCT02453711 -
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT02527200 -
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
|
Phase 3 | |
Completed |
NCT02958085 -
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight
|
Phase 1 | |
Terminated |
NCT00665665 -
Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers
|
Phase 1 | |
Completed |
NCT04156165 -
The Effect of High vs. Moderate Protein Consumption on Human Health
|
N/A | |
Recruiting |
NCT03669809 -
The Biological Rhythm of Human Metabolite
|
||
Completed |
NCT02079870 -
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
|
Phase 1 | |
Completed |
NCT03095807 -
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
|
Phase 1 | |
Recruiting |
NCT05785221 -
Lifestyle Intervention on Metabolic Homeostasis
|
N/A |